What is the prognosis for patients with metastatic uveal melanoma, specifically for HLA‑A*02:01‑positive patients treated with tebentafusp as first‑line therapy compared with HLA‑A*02:01‑negative patients?

Prognosis for Metastatic Uveal Melanoma by HLA-A*02:01 Status

HLA-A*02:01-positive patients with metastatic uveal melanoma treated with first-line tebentafusp have a significantly improved prognosis compared to standard therapies, with median overall survival of 21.6-21.7 months versus 16-16.9 months with investigator's choice therapy (HR 0.51-0.68), and 5-year survival rates of 16% versus 8%. 1, 2, 3, 4

HLA-A*02:01-Positive Patients on Tebentafusp

The prognosis for this population has been transformed by tebentafusp, representing the first systemic therapy to demonstrate survival benefit in metastatic uveal melanoma:

Survival Outcomes

• Median overall survival: 21.6-21.7 months 1, 2, 3, 4
• 1-year survival: 73% 5
• 3-year survival: 27% 3
• 5-year survival: 16% 4
• Hazard ratio for death: 0.51-0.68 compared to controls 1, 3, 4

Progression-Free Survival

• Median PFS: 3.3-3.9 months 1, 2, 6
• 6-month PFS: 31% versus 19% in controls (HR 0.73) 1, 5

The modest PFS despite substantial OS benefit reflects that traditional RECIST criteria may not fully capture clinical benefit with tebentafusp. Disease control rate is more predictive than objective response rate (ORR 9.1%) 1, 2. Importantly, patients who continued tebentafusp beyond radiographic progression had longer overall survival than those who discontinued 4.

Prognostic Factors Within HLA-A*02:01-Positive Population

Favorable prognostic indicators:

• Baseline LDH <2× ULN 7
• Lower liver metastatic burden 7
• Undetectable circulating tumor DNA (ctDNA) at baseline 4
• ctDNA reduction ≥50% by week 9 4

Poor prognostic indicators:

• Baseline LDH ≥2× ULN confers very poor prognosis 7
• Baseline tumors ≥10 cm 4

Notably, even patients with poor prognostic features (large tumor burden, progressive disease as best response) still derived survival benefit from tebentafusp 4.

Real-World Data Confirmation

Real-world evidence from the UK Expanded Access Programme (88 patients, 71% first-line) confirmed trial results with median OS of 21 months and 12-month survival of 75%, demonstrating reproducibility outside clinical trials 7. A meta-analysis of 997 patients across 12 cohorts showed consistent median OS of 21.2 months and median PFS of 3.9 months 6.

HLA-A*02:01-Negative Patients

For HLA-A*02:01-negative patients with metastatic uveal melanoma, no specific systemic therapy can be recommended based on survival benefit, and prognosis remains poor. 1

Historical Prognosis Without Effective Therapy

• Median survival after metastasis detection: 9 months (range 1-54 months) 8
• Median survival with liver involvement: 7 months 8
• Median survival without liver involvement: 19 months 8
• 1-year survival with standard therapies: approximately 50% 5

Failed Therapeutic Options

Multiple therapies have been evaluated without demonstrating OS benefit:

• Selumetinib: Improved PFS (HR 0.46) but no OS benefit (HR 0.66) in phase II; subsequent phase III SUMIT trial showed no PFS (HR 0.78, P=0.32) or OS benefit (HR 0.75, P=0.40) 1
• Hepatic intra-arterial fotemustine: Improved PFS (HR 0.62) but no OS benefit (HR 1.09) in EORTC 18021 trial 1
• Checkpoint inhibitors (pembrolizumab, ipilimumab): No proven survival benefit in uveal melanoma 1, 2

Clinical Recommendation

ASCO guidelines explicitly state: "For all patients with uveal melanoma other than those addressed by recommendation 4.1.1 [HLA-A*02:01-positive on tebentafusp], no recommendation for or against any specific systemic therapy may be made at this time. Patients should be offered or referred for enrollment in clinical trials where possible." 1

Key Clinical Implications

Testing Imperative

All patients with metastatic uveal melanoma must undergo HLA-A*02:01 genotyping to determine eligibility for tebentafusp, as this represents the only therapy with proven survival benefit 1, 2.

Treatment Beyond Progression

Post-hoc analysis suggests continuing tebentafusp beyond radiographic progression may provide survival benefit, particularly given the disconnect between traditional response criteria and clinical benefit 4.

Toxicity Profile

While grade 3-4 adverse events are substantial with tebentafusp (cytokine-mediated events 67%, cutaneous events 64%), these predominantly occur during the first 3-4 doses and become manageable over time, with only 2% discontinuation rate 1, 3, 7, 6. No treatment-related deaths have been reported 3, 5.

Liver Metastases Impact

Liver involvement (present in 87-94% of patients) significantly worsens prognosis, particularly when present at initial metastatic presentation 2, 8. However, tebentafusp provides survival benefit even in patients with extensive liver disease 4.